scPharmaceuticals
SCPH
SCPH was delisted on the 6th of October, 2025.
31 hedge funds and large institutions have $108M invested in scPharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 12 increasing their positions, 11 reducing their positions, and 9 closing their positions.
10% more capital invested
Capital invested by funds: $97.9M → $108M (+$10M)
9% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 11
0.74% more ownership
Funds ownership: 58.58% → 59.32% (+0.74%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
18% less funds holding
Funds holding: 38 → 31 (-7)
78% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$3.54M |
| 2 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$817K |
| 3 |
JGC
J. Goldman & Co
New York
|
+$428K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$206K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$179K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Russell Investments Group
London,
United Kingdom
|
-$1.19M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
-$1.16M |
| 3 |
Goldman Sachs
New York
|
-$704K |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$238K |
| 5 |
BFM
Boothbay Fund Management
New York
|
-$228K |
SCPH Hedge Fund Activity: Q3 2021 in Review
31 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in scPharmaceuticals (SCPH) for Q3 2021, worth a combined $108M — up 10% from $97.9M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of SCPH and 2 opened new positions — a net loss of 7 holders — while 11 trimmed existing stakes and 12 added.
The largest buyer was AIGH Capital Management, adding an estimated $3.54M. The largest seller was Russell Investments Group, exiting entirely with an estimated $1.19M sold.
- 31 institutional investors held scPharmaceuticals (SCPH) as of Q3 2021, down from 38 in Q2 2021.
- Funds reported $108M of scPharmaceuticals stock for Q3 2021, up 10% quarter-over-quarter.
- 2 funds opened new scPharmaceuticals positions in Q3 2021 and 9 closed out, a net change of -7 holders.
- The largest scPharmaceuticals buyer in Q3 2021 was AIGH Capital Management, an estimated $3.54M added.
- The largest scPharmaceuticals seller in Q3 2021 was Russell Investments Group, an estimated $1.19M sold.
Based on aggregated 13F filings for Q3 2021.